Medical Marijuana Inc (MJNA)

[mchat]

Medical Marijuana, Inc. Portfolio Company KannaLife Sciences Covered by International Press for …
Posted by: admin Posted date: August 20, 2014 In: News

Aug 20, 2014

OTC Disclosure & News Service

-

SAN DIEGO, Aug. 20, 2014 (GLOBE NEWSWIRE) — From the US to Turkey, the world is “buzzing” with the news that the National Institutes of Health, a U.S. Government Agency division of the Department of Health and Human Services, has approved KannaLife’s drug discovery plan for using cannabis as the source for a new drug that will treat a concussion syndrome called Chronic Traumatic Encephalopathy or “CTE.”

Medical Marijuana, Inc. (OTC Pink: MJNA) is proud to announce that one of its investment portfolio companies, KannaLife Sciences, Inc. (“KannaLife”), is the subject of this tremendous amount of mainstream news coverage. MJNA directly owns 16.70% of KannaLife’s capital stock.

KannaLife co-founder Thoma Kikis stated in a recent interview, “On the FDA drug pipeline, we are focused on treating diseases that affect the brain.” Kikis went on to explain that “CTE is a concussion-induced disease with long-term effects mostly suffered by football, hockey, soccer players and boxers.”
http://www.ganjanews.org/news/medical-marijuana-inc-portfolio-company-kannalife-sciences-covered-by-international-press-for.html